TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05717153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyamine Transport Inhibitor AMXT-1501 Dicaprate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resection
Description: Undergo surgical resection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Undergo Microdialysis

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microdialysis
Description: Undergo Microdialysis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis
Description: Undergo Microdialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement
Description: Undergo placement of catheters

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placement
Description: Undergo placement of catheters

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement
Description: Undergo placement of catheters
Study: NCT05647798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sugar check every 2 hours
Description: Blood sugar check every 2 hours

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sugar check every 4 hours
Description: Blood sugar check every 4 hours
Study: NCT06414590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebentafusp-Tebn
Description: Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.
Study: NCT06056193

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Revascularisation procedures will be performed according to randomised list

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Angioplasty
Description: Revascularisation procedures will be performed according to randomised list
Study: NCT05191277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 'discontinuation of antidepressant medication'
Description: Pharmacological intervention: Participants will discontinue their antidepressant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 'discontinuation of antidepressant medication'
Description: Pharmacological intervention: Participants will discontinue their antidepressant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 'continuation of antidepressant medication'
Description: Pharmacological intervention: Participants will remain on their antidepressant medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 'continuation of antidepressant medication'
Description: Pharmacological intervention: Participants will remain on their antidepressant medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation 'high'
Description: Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation 'high'
Description: Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the open trial arms, participants will receive full information about their treatment (i.e., high expectation). expectation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation 'moderate'
Description: Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectation 'moderate'
Description: Psychological intervention: Participants' expectations will be manipulated by varying verbal instructions using the open-hidden paradigm. Within the hidden trial arms, participants will be informed about a 50% chance of discontinuing versus remaining on their antidepressant medication (i.e., moderate expectation).
Study: NCT05617482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: All patients undergoing ceaserian section under general anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: All patients undergoing ceaserian section under general anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: All patients undergoing ceaserian section under general anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal, iliohypogastric nerve blocks
Description: In ilioinguinal-iliohypogastric block group, the probe will be placed medial to the lateral one-third of the line joining the umbilicus and the anterior superior iliac spine (ASIS). The anterior superior iliac crest, iliacus muscle, internal oblique, transverses abdominis, and the ILIH nerves between them will be identified. After appreciating the sonoanatomy, the ILIH nerve will be approached with the 23-gauge Quincke spinal needle through in-plane technique and 10 ml of 0.25% bupivacaine will be injected all around and the drug spread will be appreciated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: In TAP block group, the probe will be placed perpendicular to the mid-axillary line between the iliac crest and the subcostal margin and the three abdominal muscle layers will be identified, and the transverses abdominis plane will be located between the internal oblique and the transverse abdominis muscle. The TAP will be approached through in-plane technique using a 23-gauge Quincke spinal needle attached to a 20 ml syringe of 0.25% bupivacaine will be injected and the drug spread in the plane will be observed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: For the QLB, the transducer will be placed at the level of the anterosuperior iliac spine and will move cranially until the 3 abdominal wall muscles will be clearly identified. The external oblique muscle will be followed posterolaterally until its posterior border was visualized (hook sign), leaving underneath the internal oblique muscle, like a roof over the quadratus lumborum muscle. The probe will be tilted down to identify a bright hyperechoic line that corresponded with the middle layer of he thoracolumbar fascia. The needle (21 gauge) will be inserted in plane from anterolateral to posteromedial. The optimal point of injection for the QL block will be determined over the lumbar interfacial triangle using hydrodissection.
Study: NCT05178667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: Food supplements are consumed during 3 months by healthy volunteers.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose
Description: Food supplements are consumed during 3 months by healthy volunteers.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Food supplements are consumed during 3 months by healthy volunteers.
Study: NCT05630482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Family Foundations
Description: Healthy Family Foundations Curriculum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study: NCT06318715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified deep extubation (mDE)
Description: The proposed study is to compare a modified DE technique, which is regularly used for low-risk patients by staff anesthesiologists at our institution, to a standard awake extubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard awake extubation
Description: awake extubation (AE) is still considered the standard practice.
Study: NCT05453123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telerehabilitation
Description: examine the effect of the text message platform (WhatsApp) on the adherence to home exercise programs, pain and physical function among middle age and older adults with knee OA in two public hospitals in Riyadh city, Saudi Arabia.
Study: NCT04855851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAIN NEUROSCIENCE EDUCATION AND STRENGTH TRAINING
Description: The subjects of this group will receive an amount of six sessions that will be applied within 12 weeks. Every 15 days, the subjects will come for a consultation to receive a PNE session and review of the exercise program, which will be carried out 3 times a week for 12 weeks.
Study: NCT05369273

Intervention type: OTHER
Group type: OTHER
Intervention: intra-articular injection
Description: intra-articular injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intra-articular injection
Description: intra-articular injection

Intervention type: RADIATION
Group type: OTHER
Intervention: RMI SCANS
Description: AT 1 MONTHS BEFORE THE INTERVENTION

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RMI SCANS
Description: AT 1 MONTHS BEFORE THE INTERVENTION

Intervention type: OTHER
Group type: OTHER
Intervention: RMI SCANS
Description: AT 1MONTH AFTER THE INTERVENTION

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMI SCANS
Description: AT 1MONTH AFTER THE INTERVENTION

Intervention type: OTHER
Group type: OTHER
Intervention: RMI SCAN
Description: AT 6 MONTHS AFTER THE INTERVENTION

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RMI SCAN
Description: AT 6 MONTHS AFTER THE INTERVENTION
Study: NCT05100082

Intervention type: DRUG
Intervention: Cabozantinib
Description: Cabozantinib tablets
Study: NCT06050187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant casts fabrication
Description: four implant casts fabricated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant casts fabrication
Description: four implant casts fabricated
Study: NCT05972031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred integrated care intervention
Description: See arm description.
Study: NCT04855851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USUAL CARE
Description: Aerobic exercises will consist of a standard table of low intensity stretching exercises, commonly prescribed to fibromyalgia patients. There will be three series of 30 seconds of each stretch, having a total duration of approximately 40 minutes. Each session will be held twice a week, following the recommendations of the American College of Sport Medicine. Monitoring will be performed every 15 days by a physiotherapist.
Study: NCT04685057

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention with a daily dose of placebo for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intervention with a daily dose of probiotic for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up probiotic
Description: Intervention with a daily dose of probiotic for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-up probiotic
Description: Intervention with a daily dose of probiotic for 6 months
Study: NCT06384196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identity-Based Transdiagnostic Therapy (IBTT)
Description: In this study, IBTT is applied in 16, one-hour weekly sessions based on contemporary constructivist psychotherapy enhanced with the technological platform EYME-Explore Your Meanings to enable the immersive exploration of the patient's self-identity. Although it could be applied to other populations, IBTT has been designed to improve the mental health of late adolescents and young people.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: In this study, the UP is applied in 16, one-hour weekly sessions based on contemporary cognitive and behavioral techniques.
Study: NCT06336720

Intervention type: DEVICE
Group type: OTHER
Intervention: Portable Neuromodulation Stimulator (PoNS)
Description: The active PoNS device delivers amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes.
Study: NCT06132126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3938577
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3938577
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Administered SC.
Study: NCT04937803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus-Eluting Coronary Stent
Description: Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .
Study: NCT06164080

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: participants receiving Corticosteroid
Description: Pregnant women using antenatal corticosteroids for any reason before 34 weeks
Study: NCT04956172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroCatch Platform 2
Description: To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform 2
Description: To elicit the ERP components of interest in this study (N100, P300, N400), proprietary auditory stimulus sequences will be administered using the NeuroCatch Platform 2, an investigational medical device. Each sequence consists of tones and word pairs to elicit the various components of interest. The NeuroCatch Platform 2 consists of a computerized acquisition software which presents the stimulus, acquires the data and presents the amplitude and latency values of the ERP components (N100, N400, P300)
Study: NCT05534256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Less Program
Description: The intervention group will target a 120 minute per day reduction in sedentary behavior using an objective activity monitor and mHealth. Outcomes will be measured at baseline and post-intervention
Study: NCT04708210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI319
Description: Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.
Study: NCT04252768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eftilagimod Alpha
Description: The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneosuly as monotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15.
Study: NCT06448676

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Head-to-head comparison of all commercially available botulinum neurotoxin type A products
Study: NCT05696288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Respiratory Gas Delivery System
Description: Oxygen therapy during general anesthesia for ENT panendoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Gas Delivery System
Description: Oxygen therapy during general anesthesia for ENT panendoscopy
Study: NCT05179135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial exercise of different modalities
Description: Physical exercise performed 60 minutes after a standardized meal, of different modalities (4 different modalities will be examined, as described in the Arms)
Study: NCT05424081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMBER
Description: Self-help tool to increase weight management engagement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: List of weight management programs
Study: NCT05356897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO
Study: NCT05965258

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance (CMR)
Description: Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance (CMR)
Description: Cardiac magnetic resonance (CMR) at 6 months. If referred to MitraClip, CMR will be performed at 6 months from the procedure.
Study: NCT05647408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The nominal doses were similar, volunteers were randomly assigned to receive a single dose of DXM by IV bolus of 1.5 mL (equivalent to 6 mg of dexamethasone) or the same dose intranasally by using a Mucosal Atomization Device (MAD Nasal). allowing direct pharmacokinetic comparison without dose normalization. Venous blood samples were obtained via an indwelling catheter before administration and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, 12 and 24 h for DXM. Plasma was separated and frozen at -70 °C for further analysis.
Study: NCT05753371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 500 MG
Description: Metformin is an antihyperglycemic drug used in the management of type-2 diabetes. Metformin hydrochloride improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.